A new study paves the way for the development of next generation therapeutics for the prevention and treatment of Clostridioides difficile infection (CDI), the most frequent cause of healthcare-acquired gastrointestinal infections and death in developed countries.
The June issue of AJG includes articles on the effectiveness of OTC therapies and green kiwifruit as a dietary therapy for chronic constipation, as well as new ACG Guidelines on the Prevention, Diagnosis, and Treatment of C. difficile infections, and more.
A new study shows that the inflammation caused by Clostridioides difficile (C. diff) infection gives the pathogen a two-fold advantage: by both creating an inhospitable environment for competing bacteria and providing nutrients that enable C. diff to thrive.
Popular diets low in carbs and high in fat and protein might be good for the waistline, but a new UNLV study shows that just the opposite may help to alleviate the hospital-acquired infection Clostridioides difficile. The results appeared in a study published Feb. 11 in mSystems, an open access journal of the American Society for Microbiology.
– Researchers from the University of Maryland School of Medicine and their colleagues have identified the structure of the most lethal toxin produced by certain strains of Clostridium difficile bacteria, a potentially deadly infection associated with the use of antibiotics. The researchers mapped out the delivery and binding components of the toxin, which could pave the way for new drugs to neutralize it.